AbbVie Inc. $ABBV Shares Acquired by Cambridge Investment Research Advisors Inc.

Key Points

• Cambridge Investment Research Advisors increased its AbbVie stake by 1.8% in the fourth quarter, adding 9,761 shares and bringing its total holdings to 545,217 shares worth about $124.6 million.
• AbbVie reported strong quarterly results, with EPS of $2.65 beating estimates and revenue of $15 billion topping expectations, helped by 12.4% year-over-year revenue growth.
• The company continues to reward shareholders with a quarterly dividend of $1.73 per share, equal to an annualized yield of 3.3%, while analysts maintain a Moderate Buy outlook and average price target of $253.43.

Cambridge Investment Research Advisors Inc. lifted its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 1.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 545,217 shares of the company's stock after buying an additional 9,761 shares during the quarter. Cambridge Investment Research Advisors Inc.'s holdings in AbbVie were worth $124,577,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ABBV. Vanguard Group Inc. lifted its stake in AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company's stock valued at $41,155,601,000 after buying an additional 448,554 shares during the last quarter. Public Sector Pension Investment Board increased its holdings in shares of AbbVie by 17.0% in the third quarter. Public Sector Pension Investment Board now owns 1,044,690 shares of the company's stock valued at $241,888,000 after purchasing an additional 151,644 shares during the period. Thornburg Investment Management Inc. increased its holdings in shares of AbbVie by 25.5% in the third quarter. Thornburg Investment Management Inc. now owns 401,760 shares of the company's stock valued at $93,024,000 after purchasing an additional 81,625 shares during the period. Channing Capital Management LLC increased its holdings in shares of AbbVie by 10.5% in the third quarter. Channing Capital Management LLC now owns 55,647 shares of the company's stock valued at $12,885,000 after purchasing an additional 5,302 shares during the period. Finally, Procyon Advisors LLC increased its holdings in shares of AbbVie by 19.9% in the fourth quarter. Procyon Advisors LLC now owns 32,752 shares of the company's stock valued at $7,484,000 after purchasing an additional 5,427 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Price Performance

Shares of ABBV stock opened at $210.54 on Friday. The business's fifty day moving average price is $210.27 and its 200 day moving average price is $220.10. AbbVie Inc. has a 1-year low of $180.25 and a 1-year high of $244.81. The firm has a market capitalization of $371.98 billion, a PE ratio of 103.71, a P/E/G ratio of 0.73 and a beta of 0.32.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the prior year, the company posted $2.46 earnings per share. AbbVie's quarterly revenue was up 12.4% on a year-over-year basis. Equities research analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend was Wednesday, April 15th. AbbVie's dividend payout ratio is currently 340.89%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Barclays assumed coverage on AbbVie in a report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 target price on the stock. Morgan Stanley boosted their target price on AbbVie from $270.00 to $278.00 and gave the company an "overweight" rating in a report on Thursday, April 30th. Citigroup dropped their target price on AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a report on Tuesday, January 27th. Bank of America raised AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 target price on the stock in a report on Thursday, April 30th. Finally, DZ Bank raised AbbVie from a "hold" rating to a "strong-buy" rating in a report on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $253.43.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company's stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?
• Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably. Article: AbbVie analyst estimate update
• Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.